How should sildenafil be initiated, including appropriate dosing, contraindications, drug interactions, and dose adjustments for hepatic or renal impairment?

Sildenafil Initiation and Dosing

For erectile dysfunction, initiate sildenafil at 50 mg taken approximately 1 hour before sexual activity, with sexual stimulation required for efficacy; adjust to 25 mg if side effects occur or increase to 100 mg if inadequate response. 1

Initial Dosing by Indication

Erectile Dysfunction

• Standard starting dose: 50 mg taken 1 hour before sexual activity 1
• Dose adjustment:
  • Decrease to 25 mg if major side effects develop 1
  • Increase to 100 mg if lack of efficacy 1
• Frequency: Maximum once daily 2
• Critical requirement: Sexual stimulation is necessary for drug effect 1

Pulmonary Arterial Hypertension (PAH)

• FDA-approved dose: 20 mg three times daily (TID) 2
• Dosing interval: 4-6 hours apart 2
• Important caveat: Although FDA-approved at 20 mg TID, clinical trials demonstrated dose-response up to 80 mg TID 3
• Dose escalation strategy: For inadequate response at 20 mg TID, consider increasing in 20 mg increments to maximum 80 mg TID 3

Absolute Contraindications

Sildenafil is absolutely contraindicated with concurrent nitrate use in any form due to severe hypotension and syncope risk. 1, 2

Nitrate Contraindication Details

• All forms prohibited: tablets, patches, sprays, ointments, sublingual preparations 2
• Street drugs: "Poppers" (amyl nitrate/nitrite) 2
• Suggested safe intervals after sildenafil use:
  • 24 hours for sildenafil before nitrate administration 4
  • 48 hours for tadalafil (for comparison) 4

Other Contraindications

• Riociguat co-administration: Risk of systemic hypotension when combined with PDE5 inhibitors 3
• Allergy to sildenafil or formulation components 2

Critical Drug Interactions

Strong CYP3A4 Inhibitors (Require Dose Reduction)

Reduce sildenafil starting dose to 25 mg when co-administered with potent CYP3A4 inhibitors. 5, 6

• Ketoconazole: Contraindicated per some guidelines 7
• Ritonavir, saquinavir: Significant interaction requiring dose adjustment 5
• Erythromycin, cimetidine: Moderate inhibition 5
• Boceprevir: Increases sildenafil exposure 2.7-fold; use 25 mg starting dose 8

Drugs Requiring Caution

• Calcium channel blockers (amlodipine): Additive blood pressure lowering (8/7 mmHg additional decrease), but not synergistic 9
• Antihypertensives: Monitor blood pressure; sildenafil efficacy not affected by concurrent use 5
• Alpha-blockers: Use caution due to additive hypotensive effects

Contraindicated Combinations

• Class I and III antiarrhythmics: Amiodarone, flecainide, propafenone, quinidine, bepridil (risk of QT prolongation) 7
• Ergot derivatives: Serious risk from CYP3A4 inhibition 7
• Oral midazolam 7
• Cisapride 7

Dose Adjustments for Organ Impairment

Hepatic Impairment

Start with 25 mg for moderate to severe hepatic impairment due to 47% increase in exposure and 46% reduction in clearance. 6

• Mild to moderate impairment: No dose adjustment required per FDA label 2, but consider 25 mg starting dose based on pharmacokinetic data 6
• Severe impairment (Child-Pugh C): Not studied; use with extreme caution if at all 2
• Mechanism: Reduced first-pass metabolism and systemic clearance 6

Renal Impairment

For severe renal impairment (CrCl <30 mL/min), initiate at 25 mg due to increased drug exposure. 6

• Mild to moderate impairment: No dose adjustment required per FDA label 2
• Severe impairment (CrCl <30 mL/min): Significant increases in Cmax and AUC; start with 25 mg 6
• End-stage renal disease: Use with caution 2

Elderly Patients (≥65 years)

Consider 25 mg starting dose in elderly patients due to approximately 2-fold higher AUC and 60-70% higher Cmax. 6

• Pharmacokinetic changes: Doubled AUC, 60-70% higher Cmax, longer half-life (1 hour longer for sildenafil, 2 hours for metabolite) 6
• Free drug concentrations: Only 40% higher due to increased protein binding 6
• Clinical consideration: Greater frequency of comorbidities and polypharmacy 2

Common Side Effects and Management

Most adverse events are mild to moderate and transient. 1, 10

Frequent Side Effects (dose-related)

• Headache
• Flushing
• Dyspepsia
• Nasal congestion
• Dizziness
• Myalgias

Visual Disturbances

• Mechanism: PDE6 inhibition in retina 1
• Symptoms: Blue-green color discrimination difficulty, bluish vision, difficulty seeing in dim light 1
• Serious concern: Sudden vision loss (NAION) - discontinue immediately 2

Cardiovascular Considerations

• Hypotension: Transient blood pressure reduction; more pronounced with nitrates 5, 9
• Syncope risk: Particularly with first dose of intraurethral alprostadil (different drug, but illustrates PDE5i cardiovascular effects) 4

Optimizing Treatment Success

Failure to respond often reflects inadequate trial rather than true treatment failure. 4

Common Reasons for Treatment Failure

• Inadequate sexual stimulation 4
• Incorrect timing (not waiting 1 hour) 1
• Taking with large/high-fat meal (delays absorption) 5
• Insufficient dose titration 4
• Heavy alcohol use 4
• Unaddressed hormonal abnormalities (hypogonadism) 4, 10
• Drug interactions 4

Re-education Strategy

Before declaring treatment failure, ensure proper administration: adequate dose (up to 100 mg), correct timing (1 hour before activity), sexual stimulation, and address modifiable factors. 4

Combination with Testosterone

In men with erectile dysfunction and testosterone deficiency, combining sildenafil with testosterone therapy is more effective than sildenafil alone. 10

• Testosterone alone is not effective monotherapy for ED 10
• PDE5 inhibitors may be more effective when testosterone deficiency is corrected 10

Special Populations

Diabetes Mellitus

• Sildenafil effective but response may be less robust than general population 11, 5
• Improved glycemic control may enhance response, especially in newly diagnosed patients 1

Post-Prostatectomy

• More severe baseline ED; less robust response to PDE5 inhibitors 10
• Early use (within 45 days) does not improve unassisted erectile function but effective on-demand 10

Cardiovascular Disease

• Effective in patients with cardiovascular disease 11
• Ensure no concurrent nitrate use 1, 2
• Monitor for cardiovascular status changes during follow-up 4

Pediatric Use (PAH only)

Chronic sildenafil use is not recommended in children due to increased mortality with higher doses observed in the STARTS-2 trial. 12, 2

• Age <1 year: 0.5-1 mg/kg TID 12
• Weight-based dosing for older children 12
• FDA warning for ages 1-17 years 12
• Delay use in extremely preterm infants until retinal vascularization established 12

Monitoring Requirements

Periodic follow-up should assess efficacy, side effects, and changes in health status including new medications. 4

• Typically performed at prescription renewal 4
• Cardiovascular status reassessment 4
• Medication reconciliation (especially nitrates, CYP3A4 inhibitors) 4